Sweden, Denmark, Spain, Estonia, Belgium, Poland, Norway, Türkiye, Portugal, France, United Kingdom, Italy, Greece – Research and development services and related consultancy services – RESEARCH AND DEVELOPMENT SERVICES AND RELATED CONSULTANCY SERVICESOPEN MARKET CONSULTATION OF PROCURE4HEALTH FOR THE FUTURE PRE-COMMERCIAL PROCUREMENT OF R&D SERVICES CONCERNING THE PRESERVATION OF FRESH BIOLOGICAL SAMPLES.
Åpne hos TED ↗ ☆ BokmerkSammendrag fra kunngjøring og vedlegg (AI-generert)
Hva skal kjøpes inn?
Det skal kjøpes inn forsknings- og utviklingstjenester knyttet til bevaring av ferske biologiske prøver. Målet er å utvikle kostnadseffektive metoder for å bevare biologiske prøver uten frysing, samtidig som integriteten og utbyttet av DNA, RNA, proteiner og metabolitter opprettholdes.
Sentrale krav til leverandør
- Leverandører må kunne tilby løsninger som oppfyller funksjonelle krav.
- Teknologileverandører vil bli valgt for fase 1 basert på teknisk og økonomisk gjennomførbarhet.
- Deltakelse i prosjektet krever evne til å dele risiko og fordeler under markedsforhold.
Praktiske forhold
- Prosjektet er delt inn i tre faser: løsningdesign, prototypeimplementering, og validering og demonstrasjon.
- Det er ikke spesifisert noen kontraktslengde eller antall leveranser per år.
- PCP-anskaffelsen er unntatt fra WTO GPA, EU-direktiver og nasjonale lover.
Tildelingskriterier
Ikke spesifisert i utdraget.
Generert fra kunngjøring og 0 vedlegg. Les originaldokumentene for autoritative krav.
Beskrivelse
This Prior Information Notice announces the Open Market Consultation conducted by the PROCURE4HEALTH project and provides information about a potential future Pre-Commercial Procurement (PCP) of R&D services concerning the preservation of fresh biological samples. PROCURE4HEALTH aims to challenge the market to develop innovative solutions for advancing the preservation of biological samples for molecular biology studies. This initiative addresses the need for cost-efficient methods to preserve biological samples - ensuring the integrity and high yield of DNA, RNA, proteins, and metabolites - without requiring freezing and its associated infrastructure. These advancements are crucial for enhancing translational research, optimizing disease management, and improving patient outcomes in the context of precision medicine. PCP is an approach that allows public procurers to buy R&D from several competing suppliers in parallel, to compare alternative solution approaches, and to identify the best value-for-money solutions that the market can deliver to address their needs. It is split into three phases: solution design, prototype implementation, and validation and demonstration of the solutions. In PCP, there is a risk-benefit sharing under market conditions between the public procurer and the suppliers, and a clear separation between the PCP and the deployment of commercial volumes of end-products. The PCP procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. The future PCP will be composed of three phases: Phase 1. Solution design: Phase 1 of the PCP will deal with the design of the solutions and verification of their technical and economic feasibility based on functional requirements. It will be implemented according to the tender documents in compliance with the procurement principles and the PCP methodology. Several technology providers will be selected for this phase. Phase 2. Prototype implementation: Phase 2 of the PCP concerns the development of the first prototypes of the solutions and testing at the procurers’ premises under controlled conditions. Several technology providers will be selected for this phase. Phase 3. Validation and demonstration of the solutions: Phase 3 of the PCP will deal with testing and validation of the selected solutions in operational environments. It will take place in several Member States. A minimum of 2 operators per challenge will be selected for this phase. The selected operators will retain ownership of the Intellectual Property Rights (IPRs) that they will generate during the PCP and will be able to use them to exploit the full market potential of the developed solutions. This PIN invites all interested technology providers from EU Member States and Associated Countries committed to perform R&D in the EU and/or Associated Countries, regardless of their size or governance structure, to take part in the Open Market Consultation. The Open Market Consultation aims to: (1) Validate the findings of the state-of-the-art analysis and the viability of the set of technical and financial provisions. (2) Raise awareness to the industry regarding the upcoming pre-commercial procurement (PCP). (3) Collect insights from the industry which can be used to fine tune the tender specifications. The market consultation may include one or more events, and a questionnaire to request information from the market. This Prior Information Notice is not a commitment to procure. The contracting authorities involved are not legally bound in any way by the outcome of the market consultation. No advantage or disadvantage will be given to any supplier /group of suppliers to the detriment of others during the market consultation and the sub-sequent competitive procedure for the award of contracts. The official communication language is English. The Open Market Consultation document will be published on the PROCURE4HEALTH website (www.procure4health.eu). The project has received funding from the Horizon Europe Framework Programme (HORIZON) under grant agreement n. 101057209. However, the European Union will not participate as a contracting authority in the procurement
Få full anbudsanalyse (PDF)
4-siders rapport med kjøperens historikk, sannsynlige konkurrenter, pris-benchmark og risiko-signaler. 199 kr per anbud. Pro-abonnenter får 10/mnd inkludert.
Bransjekoder (CPV)
73000000 - Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester 85100000 - Tjenesteytelser innen helsevesenetOm denne anskaffelsen
Denne kunngjøringen ble publisert på TED (EU) 9. juli 2024 av Servicio Andaluz de Salud.
Tilbydere bør lese hele konkurransegrunnlaget nøye og merke seg kvalifikasjonskrav, tildelingskriterier og frister. Spørsmål til konkurransen rettes til oppdragsgiver.
Lignende anbud
Flere anbud i samme bransje
- Norway – Research and development services and related consultancy services – Avinor AS - T-193433 - Demonstration of zero and low emission aircraft VTOL · AVINOR AS (28.10.2026)
- Norway – Research and development services and related consultancy services – Qualification scheme - Avinor AS - T-193432 - Demonstration of zero and low emission aircraft regional aviation · AVINOR AS (28.10.2026)
- Kontraktstildeling - Seniorressurs med teknisk og økonomisk kompetanse - Dynamisk innkjøpsordning - Arkitektur · Digitaliseringsdirektoratet · tildelt (27.10.2026)
- Markedsdialog (RFI) Konsulentformidling innenfor IKT · DEPARTEMENTENES DIGITALISERINGSORGANISASJON (DIO) · avsluttet (26.10.2026)
- Rammeavtale om bydelsreform · Oslo kommune v/ Byrådsavdeling for helse · tildelt (26.10.2026)
- RFI - Markedsdialog - 1105601 UiO Livsvitenskap brukerutstyr - K970.05 Høytrykksfryser · Statsbygg (26.10.2026)
- RFI - Markedsdialog - 1105601 UiO Livsvitenskap brukerutstyr. K970.04.02 Kryo-ultramikrotom · Statsbygg (26.10.2026)
- Kartlegging av organisatoriske løsninger på tolkefeltet (TOLKORG) · Integrerings- og mangfoldsdirektoratet (IMDi) (25.10.2026)
- Innvandrerkvinner i og utenfor arbeid - KVINARB · Integrerings- og mangfoldsdirektoratet (IMDi) · tildelt (23.10.2026)
- Operasjonalisering og måling av politiets innsatsevne på beredskapsområdet · Politiets fellestjenester (23.10.2026)